Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cyclin-Dependent Kinase 4"" wg kryterium: Temat


Tytuł:
DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway.
Autorzy:
Fan H; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Liu W; Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Zeng Y; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Zhou Y; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Gao M; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Yang L; Department of Gastroenterology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, Zhejiang, China.
Liu H; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.; Department of Pharmacy, China Pharmaceutical University, No. 24 Tongjiaxiang Road, Nanjing, 210009, China.
Shi Y; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Li L; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Ma J; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Ruan J; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.; Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Cao R; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.; Department of Pharmacy, China Pharmaceutical University, No. 24 Tongjiaxiang Road, Nanjing, 210009, China.
Jin X; The Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong, Jiangsu, China. .
Chen J; The Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong, Jiangsu, China. .
Cheng G; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA. .
Yang H; National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China. .; Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2023 Oct 13; Vol. 6 (1), pp. 1041. Date of Electronic Publication: 2023 Oct 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cyclin-Dependent Kinase 4*/genetics
Cyclin-Dependent Kinase 4*/metabolism
Cyclin-Dependent Kinase 6*/genetics
Cyclin-Dependent Kinase 6*/metabolism
Interferon Type I*/pharmacology
Neoplasms*/drug therapy
Neoplasms*/genetics
Humans ; Immunity ; Nucleotidyltransferases/genetics ; Nucleotidyltransferases/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł:
CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment.
Autorzy:
Gu H; Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Chen Y
Xie Z
Chen Y
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2023 Oct 06; Vol. 102 (40), pp. e35487.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Cyclin-Dependent Kinase 4*/antagonists & inhibitors
Protein Kinase Inhibitors*/therapeutic use
Antineoplastic Agents*/therapeutic use
Cyclin-Dependent Kinase 6*/antagonists & inhibitors
Female ; Humans ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł:
Loss of CDK4/6 activity in S/G2 phase leads to cell cycle reversal.
Autorzy:
Cornwell JA; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Crncec A; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Afifi MM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Tang K; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Amin R; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Cappell SD; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Jul; Vol. 619 (7969), pp. 363-370. Date of Electronic Publication: 2023 Jul 05.
Typ publikacji:
Journal Article
MeSH Terms:
Cell Cycle*
Cyclin-Dependent Kinase 4*/deficiency
Cyclin-Dependent Kinase 4*/metabolism
G2 Phase*
Cyclin-Dependent Kinase 6*/deficiency
Cyclin-Dependent Kinase 6*/metabolism
S Phase*
Animals ; Cyclin A2/metabolism ; Cyclin-Dependent Kinase 2/metabolism ; Mitogens/deficiency ; Mitogens/metabolism ; Mitosis ; Phosphorylation ; Retinoblastoma Protein/chemistry ; Retinoblastoma Protein/metabolism ; G1 Phase
Czasopismo naukowe
Tytuł:
Cyclin D1-Cdk4 regulates neuronal activity through phosphorylation of GABAA receptors.
Autorzy:
Pedraza N; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain. .
Monserrat MV; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain.
Ferrezuelo F; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain.
Torres-Rosell J; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain.
Colomina N; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain.
Miguez-Cabello F; Laboratori de Neurofisiologia, Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Párraga JP; Laboratori de Neurofisiologia, Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Soto D; Laboratori de Neurofisiologia, Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
López-Merino E; Department of Molecular Neurobiology, Centro de Biología Molecular 'Severo Ochoa', Consejo Superior de Investigaciones Científicas (CSIC)/Universidad Autónoma de Madrid (UAM), Madrid, Spain.
García-Vilela C; Department of Molecular Neurobiology, Centro de Biología Molecular 'Severo Ochoa', Consejo Superior de Investigaciones Científicas (CSIC)/Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Esteban JA; Department of Molecular Neurobiology, Centro de Biología Molecular 'Severo Ochoa', Consejo Superior de Investigaciones Científicas (CSIC)/Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Egea J; Molecular and Developmental Neurobiology, Dept. Ciències Mèdiques Bàsiques, Facultat de Medicina, Universitat de Lleida/IRBLLEIDA, Rovira Roure 80, 25198, Lleida, Spain.
Garí E; Cell Cycle, Department of Basic Medical Sciences, Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), University of Lleida, Lleida, Spain. .
Pokaż więcej
Źródło:
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2023 Sep 08; Vol. 80 (10), pp. 280. Date of Electronic Publication: 2023 Sep 08.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclin D1*/genetics
Receptors, GABA-A*/genetics
Cyclin-Dependent Kinase 4*/genetics
Animals ; Mice ; Rats ; gamma-Aminobutyric Acid ; Mice, Knockout ; Neurons ; Phosphorylation
Czasopismo naukowe
Tytuł:
Astragaloside IV promotes keratinocyte proliferation and migration through upregulating lncRNA H19 recruited ILF3 to enhance the stability of CDK4 mRNA.
Autorzy:
Wang DD; The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, PR China.; Department of Anorectum, The Affiliated Hospital Of Qingdao University, Qingdao, PR China.
Zhang LZ; Department of Anorectum, The Affiliated Hospital Of Qingdao University, Qingdao, PR China.
Pang CJ; Department of Anorectum, The Affiliated Hospital Of Qingdao University, Qingdao, PR China.
Ye JZ; The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, PR China.
Pokaż więcej
Źródło:
The Kaohsiung journal of medical sciences [Kaohsiung J Med Sci] 2023 Aug; Vol. 39 (8), pp. 811-823. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
Keratinocytes*/metabolism
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Nuclear Factor 90 Proteins*/genetics
Nuclear Factor 90 Proteins*/metabolism
Cyclin-Dependent Kinase 4*/genetics
Cell Proliferation/genetics ; RNA, Messenger/genetics ; HaCaT Cells ; Humans
Czasopismo naukowe
Tytuł:
CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas.
Autorzy:
Julson JR; Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Horton SC; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Quinn CH; Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Beierle AM; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Bownes LV; Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Stewart JE; Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Aye J; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Beierle EA; Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Electronic address: .
Pokaż więcej
Źródło:
Journal of pediatric surgery [J Pediatr Surg] 2024 Mar; Vol. 59 (3), pp. 473-482. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcoma*/drug therapy
Sarcoma*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Child ; Humans ; Protein Kinase Inhibitors/pharmacology ; Retinoblastoma Protein/metabolism ; Retinoblastoma Protein/pharmacology ; Retinoblastoma Protein/therapeutic use ; Phosphorylation ; Cell Line, Tumor ; Cell Proliferation ; Cyclin-Dependent Kinase 4/metabolism ; Cyclin-Dependent Kinase 4/therapeutic use
Czasopismo naukowe
Tytuł:
CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects.
Autorzy:
Wekking D; Amsterdam UMC, Location Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: .
Leoni VP; Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Italy.
Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Dessì M; Medical Oncology AOU Cagliari Policlinico Duilio Casula, Monserrato, Cagliari, Italy.
Pretta A; Medical Oncology Unit, University Hospital and University of Cagliari, Italy.
Cadoni A; Medical Oncology Unit, University Hospital and University of Cagliari, Italy.
Atzori L; Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Italy.
Scartozzi M; Medical Oncology AOU Cagliari Policlinico Duilio Casula, Monserrato, Cagliari, Italy; Medical Oncology Unit, University Hospital and University of Cagliari, Italy.
Solinas C; Medical Oncology AOU Cagliari Policlinico Duilio Casula, Monserrato, Cagliari, Italy.
Pokaż więcej
Źródło:
Cytokine & growth factor reviews [Cytokine Growth Factor Rev] 2024 Feb; Vol. 75, pp. 57-64. Date of Electronic Publication: 2023 Oct 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Breast Neoplasms*/drug therapy
Aminopyridines*
Humans ; Female ; Cyclin-Dependent Kinase 6/pharmacology ; Cyclin-Dependent Kinase 6/therapeutic use ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Cell Cycle ; Protein Kinase Inhibitors/therapeutic use ; Cyclin-Dependent Kinase 4/pharmacology ; Cyclin-Dependent Kinase 4/therapeutic use
Czasopismo naukowe
Tytuł:
MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis.
Autorzy:
Li X; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Xie S; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Xia Q; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Yan J; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Chen S; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Shen J; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, P.R. China.; Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, P.R. China.
Pokaż więcej
Źródło:
Technology in cancer research & treatment [Technol Cancer Res Treat] 2023 Jan-Dec; Vol. 22, pp. 15330338221150544.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Cyclin-Dependent Kinase 4*/genetics
Cyclin-Dependent Kinase 4*/metabolism
Liver Neoplasms*/pathology
MicroRNAs*/metabolism
Casein Kinase II*/genetics
Casein Kinase II*/metabolism
Humans ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic
Czasopismo naukowe
Tytuł:
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Autorzy:
Lin CC; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Chang TC; Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX, USA.; Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Wang Y; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Guo L; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Gao Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Bikorimana E; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Lemoff A; Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.
Fang YV; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Zhang H; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Zhang Y; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Ye D; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Soria-Bretones I; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Servetto A; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Lee KM; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Life Science, Hanyang University, Seoul, South Korea.
Luo X; Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.
Otto JJ; Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.
Akamatsu H; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Napolitano F; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Mani R; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Cescon DW; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Xu L; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Xie Y; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Mendell JT; Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX, USA.; Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Hanker AB; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Arteaga CL; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Mar 13; Vol. 15 (1), pp. 2287. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Humans ; Female ; Cell Line, Tumor ; RNA Polymerase II ; Cyclin-Dependent Kinase 4/metabolism ; Cyclin-Dependent Kinase Inhibitor Proteins ; Cyclin-Dependent Kinase 6/genetics ; Cyclin-Dependent Kinase 6/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Protein-Arginine N-Methyltransferases/genetics ; Protein-Arginine N-Methyltransferases/metabolism
Czasopismo naukowe
Tytuł:
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
Autorzy:
Ma J; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Li L; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Ma B; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Liu T; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Wang Z; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Ye Q; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Peng Y; Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Wang B; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Chen Y; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Xu S; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Wang K; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Dang F; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Wang X; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Zeng Z; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Jian Y; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Ren Z; Kintor Parmaceutical, Inc, Suzhou, 215123, China.
Fan Y; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Li X; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Liu J; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Gao Y; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Wei W; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Li L; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. .; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China. .; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Feb 29; Vol. 15 (1), pp. 1871. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclin-Dependent Kinase Inhibitor Proteins*
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Humans ; Male ; Pelvis ; Promoter Regions, Genetic ; Prostate ; Cyclin-Dependent Kinase 4/genetics ; Cyclin-Dependent Kinase 6/genetics ; Protein Kinase Inhibitors
Czasopismo naukowe
Tytuł:
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2.
Autorzy:
Hummel JR; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Xiao KJ; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Yang JC; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Epling LB; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Mukai K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Ye Q; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Xu M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Qian D; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Huo L; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Weber M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Roman V; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Lo Y; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Drake K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Stump K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Covington M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Kapilashrami K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Zhang G; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Ye M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Diamond S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Yeleswaram S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Macarron R; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Deller MC; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Wee S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Kim S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Wang X; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Wu L; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Yao W; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 3112-3126. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclin-Dependent Kinases*
Neoplasms*
Animals ; Humans ; Mice ; Cyclin-Dependent Kinase 2 ; Cyclin-Dependent Kinase 4/metabolism ; Phosphorylation ; Pyrimidines/pharmacology ; Pyrazoles/chemistry ; Pyrazoles/metabolism ; Pyrazoles/pharmacology
Czasopismo naukowe
Tytuł:
A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Autorzy:
Zhong N; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yu D; Center of Translational Medicine, Naval Medical University, Shanghai, China.
Yang M; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lu X; State Key Laboratory of Computer Architecture, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China.
Zhang Q; State Key Laboratory of Computer Architecture, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China.
Wei W; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiao J; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yang X; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhu Z; Department of Pathology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Chen S; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. .
Xiao J; Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 19; Vol. 150 (2), pp. 95. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Chordoma*/drug therapy
Chordoma*/genetics
Chordoma*/pathology
Piperazines*
Humans ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Pyridines ; Cyclin-Dependent Kinase 4/genetics ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Tytuł:
CDK4/6 inhibitors in lung cancer: current practice and future directions.
Autorzy:
Lv S; The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; The Institute of Life Sciences, Wenzhou University, Wenzhou, China.; These authors contributed equally to this work.
Yang J; The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; The Institute of Life Sciences, Wenzhou University, Wenzhou, China.; These authors contributed equally to this work.
Lin J; Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD, USA.
Huang X; The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Zhao H; The Institute of Life Sciences, Wenzhou University, Wenzhou, China.
Zhao C; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China .
Yang L; The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China .
Pokaż więcej
Źródło:
European respiratory review : an official journal of the European Respiratory Society [Eur Respir Rev] 2024 Feb 14; Vol. 33 (171). Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Lung Neoplasms*/drug therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Humans ; Cyclin-Dependent Kinase 4/metabolism ; Cell Proliferation ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł:
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Autorzy:
Kappel C; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Elliott MJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Kumar V; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Nadler MB; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Desnoyers A; Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada.
Amir E; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. .; Princess Margaret Cancer Centre, 610 University Ave, 700U, 7-721, Toronto, ON, M5G 2M9, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 07; Vol. 14 (1), pp. 3129. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Breast Neoplasms*/drug therapy
Female ; Humans ; Aminopyridines ; Benzimidazoles ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Cyclin-Dependent Kinase Inhibitor Proteins ; Neutropenia/chemically induced ; Purines ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Autorzy:
Ji Y; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA. .
Schiller H; Novartis Institutes for Biomedical Research, Fabrikstrasse 2, 4056 Basel, Switzerland.
Yang S; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Quinlan M; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Darstein C; Novartis Institutes for Biomedical Research, Fabrikstrasse 2, 4056 Basel, Switzerland.
Huth F; Novartis Institutes for Biomedical Research, Fabrikstrasse 2, 4056 Basel, Switzerland.
Winter S; Novartis Institutes for Biomedical Research, Fabrikstrasse 2, 4056 Basel, Switzerland.
Chakraborty A; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Pokaż więcej
Źródło:
Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Feb; Vol. 63 (2), pp. 155-170. Date of Electronic Publication: 2024 Jan 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Humans ; Female ; Cytochrome P-450 CYP3A ; Aminopyridines/adverse effects ; Purines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Receptor, ErbB-2 ; Cyclin-Dependent Kinase 4
Czasopismo naukowe
Tytuł:
Intra-Abdominal and Retroperitoneal Benign Lipomatous Tumors-An Extremely Rare Mimic of Liposarcoma and its Diagnostic Challenge.
Autorzy:
Malik F; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Allbee AW; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Zhang PJ; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
International journal of surgical pathology [Int J Surg Pathol] 2024 Feb; Vol. 32 (1), pp. 46-57. Date of Electronic Publication: 2023 May 02.
Typ publikacji:
Journal Article
MeSH Terms:
Liposarcoma*/diagnosis
Liposarcoma*/genetics
Lipoma*/diagnosis
Lipoma*/genetics
Lipoma*/pathology
Male ; Female ; Humans ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; In Situ Hybridization, Fluorescence/methods ; Proto-Oncogene Proteins c-mdm2/genetics ; Cyclin-Dependent Kinase 4/genetics ; Biomarkers, Tumor
Czasopismo naukowe
Tytuł:
Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of CDK4/6 inhibitor palbociclib to melanoma.
Autorzy:
Attia MF; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. .
Ogunnaike EA; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. .
Pitz M; Department of Bioengineering, Clemson University, Clemson, SC, 29634, USA.
Elbaz NM; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. .
Panda DK; Department of Chemistry, Clemson University, Clemson, SC, 29634, USA. .
Alexander-Bryant A; Department of Bioengineering, Clemson University, Clemson, SC, 29634, USA.
Saha S; Department of Chemistry, Clemson University, Clemson, SC, 29634, USA. .
Whitehead DC; Department of Chemistry, Clemson University, Clemson, SC, 29634, USA. .
Kabanov A; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. .; Laboratory of Chemical Design of Bionanomaterials, Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, 119992, Russia.
Pokaż więcej
Źródło:
Biomaterials science [Biomater Sci] 2024 Jan 30; Vol. 12 (3), pp. 725-737. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Journal Article
MeSH Terms:
Melanoma*/drug therapy
Nanoparticles*/chemistry
Piperazines*
Pyridines*
Mice ; Humans ; Animals ; Molecular Docking Simulation ; Drug Delivery Systems ; Surface-Active Agents ; Drug Carriers/chemistry ; Cyclin-Dependent Kinase 4
Czasopismo naukowe
Tytuł:
Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy.
Autorzy:
Torrisi R; Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
Vaira V; Division of Pathology, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milano, Italy.; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milano, Italy.
Giordano L; Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
Fernandes B; Pathology Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
Saltalamacchia G; Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
Palumbo R; Oncologia Medica IRCCS ICS Maugeri, 27100 Pavia, Italy.
Carnaghi C; Clinical Trials Unit, Istituto Clinico Humanitas, Centro Catanese di Oncologia, 20072 Catania, Italy.
Basilico V; Medical Oncology Unit, Istituto Clinico Mater Domini Humanitas, Castellanza, 21100 Varese, Italy.
Gentile F; Division of Pathology, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milano, Italy.
Masci G; Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
De Sanctis R; Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
Santoro A; Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 25; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/metabolism
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Pyridines*
Humans ; Female ; Phosphatidylinositol 3-Kinases ; Piperazines/pharmacology ; Piperazines/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Receptor, ErbB-2/metabolism ; Cyclin-Dependent Kinase 4/genetics
Czasopismo naukowe
Tytuł:
The Role of CD4/6 Inhibitors in Breast Cancer Treatment.
Autorzy:
Purohit L; Memorial Health System, Pembroke Pines, FL 33024, USA.
Jones C; Memorial Health System, Pembroke Pines, FL 33024, USA.
Gonzalez T; Memorial Health System, Pembroke Pines, FL 33024, USA.
Castrellon A; Memorial Health System, Pembroke Pines, FL 33024, USA.
Hussein A; Memorial Health System, Pembroke Pines, FL 33024, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 19; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Humans ; Female ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Biomarkers ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł:
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- breast cancer: an umbrella review.
Autorzy:
Pu D; First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Xu D; College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Wu Y; College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Chen H; Breast Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, Shandong, China.
Shi G; Breast Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, Shandong, China.
Feng D; First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Zhang M; First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Liu Z; Institute for Literature and Culture of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. .; Central Laboratory, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. .
Li J; Breast Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, Shandong, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jan 19; Vol. 150 (1), pp. 16. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Meta-Analysis; Journal Article; Review
MeSH Terms:
Breast Neoplasms*
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Disease-Free Survival ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Receptor, ErbB-2
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies